Champions Oncology(CSBR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CSBR Champions Oncology

Post-Market Trading 01-08 19:34:42 EST

9.66

-0.84

-8.00%

盘后9.70

+0.04+0.41%

16:07 EST

High10.47	Low9.40	Vol48.07K
Open10.47	D1 Closing10.50	Amplitude10.23%
Mkt Cap132.33M	Tradable Cap49.28M	Total Shares13.70M
T/O470.66K	T/O Rate0.94%	Tradable Shares5.10M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CSBR","market":"US","secType":"STK","nameCN":"Champions Oncology","latestPrice":9.66,"timestamp":1736370000000,"preClose":10.5,"halted":0,"volume":48073,"hourTrading":{"tag":"盘后","latestPrice":9.7,"preClose":9.66,"latestTime":"16:07 EST","volume":268,"amount":2588.9202,"timestamp":1736370467047},"delay":0,"floatShares":5101934,"shares":13698903,"eps":-0.044036,"marketStatus":"Post-Market Trading","change":-0.84,"latestTime":"01-08 19:34:42 EST","open":10.47,"high":10.47,"low":9.3956,"amount":470661.849796,"amplitude":0.102324,"askPrice":11.28,"askSize":100,"bidPrice":9.26,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-0.044036,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1736384400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.5,"preHourTrading":{"tag":"盘前","latestPrice":10.46,"preClose":10.5,"latestTime":"09:29 EST","volume":310,"amount":3044.0202,"timestamp":1736346571107},"postHourTrading":{"tag":"盘后","latestPrice":9.7,"preClose":9.66,"latestTime":"16:07 EST","volume":268,"amount":2588.9202,"timestamp":1736370467047},"volumeRatio":0.523952,"impliedVol":0.5847,"impliedVolPercentile":0.2857},"requestUrl":"/m/hq/s/CSBR","defaultTab":"news","newsList":[{"id":"2501722053","title":"Champions Oncology integrates Cytek Aurora flow cytometers","url":"https://stock-news.laohu8.com/highlight/detail?id=2501722053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501722053?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:30","pubTimestamp":1736343047,"startTime":"0","endTime":"0","summary":"Champions Oncology (CSBR) announced advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/champions-oncology-integrates-cytek-aurora-flow-cytometers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/champions-oncology-integrates-cytek-aurora-flow-cytometers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4121","ACB","BK4557","CSBR"],"gpt_icon":0},{"id":"2501724097","title":"Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2501724097","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501724097?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. , a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of services will allow Champions to better serve its clients by offering increased depth through higher complexity spectral analysis. Champions is also pleased to welcome Troy Tremaine, who will lead the commercial strategy for this growing business vertical. As a seasoned leader in this field, Troy brings decades of e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-enhances-clinical-bioanalytical-130000210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4557","CSBR","ACB","BK4007","BK4121","PDX"],"gpt_icon":0},{"id":"2493244645","title":"Private equity firms invested in Champions Oncology, Inc. (NASDAQ:CSBR) up 19% last week, insiders too were rewarded","url":"https://stock-news.laohu8.com/highlight/detail?id=2493244645","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493244645?lang=en_us&edition=fundamental","pubTime":"2024-12-22 22:04","pubTimestamp":1734876281,"startTime":"0","endTime":"0","summary":"Significant control over Champions Oncology by private equity firms implies that the general public has more power to influence management and governance-related decisions. A look at the shareholders of Champions Oncology, Inc.  can tell us which group is most powerful. We can see that private equity firms own the lion's share in the company with 30% ownership. That is, the group stands to benefit the most if the stock rises .While private equity firms were the group that benefitted the most from last week’s US$17m market cap gain, insiders too had a 26% share in those profits.Let's delve deeper into each type of owner of Champions Oncology, beginning with the chart below.What Does The Institutional Ownership Tell Us About Champions Oncology?Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.While it makes sense to study institutional ownership data for a com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qUsXHnhTq9BjFq.vX6I3sw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qUsXHnhTq9BjFq.vX6I3sw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/private-equity-firms-invested-champions-140441494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","NDAQ","BK4588","USAW.SI","IE00B64PRP62.GBP","PSQ","CSBR","TSYW.SI","LU2210150020.SGD","NVIW.SI","QID","SQQQ","BK4112","IE00BKPKM429.USD","BK4585","TQQQ","LU2095319765.USD",".IXIC","USJW.SI","BK4121","LU2210149790.SGD","IE00BGHQF748.EUR","QLD","NQmain","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2491336663","title":"Champions Oncology Is Maintained at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2491336663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491336663?lang=en_us&edition=fundamental","pubTime":"2024-12-13 00:33","pubTimestamp":1734021180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CSBR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2024 11:33 ET (16:33 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2490466828","title":"Champions Oncology Posts Strong Quarterly Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2490466828","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490466828?lang=en_us&edition=fundamental","pubTime":"2024-12-12 11:52","pubTimestamp":1733975569,"startTime":"0","endTime":"0","summary":"Champions Oncology ( ($CSBR) ) has released its Q2 earnings. Here is a breakdown of the information Champions Oncology presented to its investors. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/champions-oncology-posts-strong-quarterly-revenue-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/champions-oncology-posts-strong-quarterly-revenue-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSBR"],"gpt_icon":0},{"id":"2490812489","title":"Stocks to Watch: Adobe, Champions Oncology, DBV Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2490812489","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490812489?lang=en_us&edition=fundamental","pubTime":"2024-12-12 07:40","pubTimestamp":1733960400,"startTime":"0","endTime":"0","summary":"Adobe's fiscal 2025 outlook missed estimates. The software maker expects revenue between $23.3 billion and $23.55 billion for the current fiscal year, missing the $23.78 billion that analysts polled by FactSet expect. It also guided for adjusted per-share earnings between $20.20 and $20.50, compared with the $20.52 for which analysts are looking. The company's lower-than-expected outlook came as it posted higher revenue and earnings in its fiscal 4Q. Shares slide 8.8%, to $501.55, in after-hours trading.Champions Oncology swung to a profit and reported higher revenue in the latest quarter due to bookings growth and operational improvements. The technology-enabled research company posted earnings of 5 cents a share on revenue of $13.5 million, compared with a loss of 15 cents a share on revenue of $11.6 million a year earlier. Chief Executive Ronnie Morris said the company is cautiously optimistic that the pharma and biotech environments are improving. Shares jump 13%, to $6.59, in post","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4527","LU0719512351.SGD","LU0109392836.USD","LU2458330243.SGD","LU1267930813.SGD","LU0289739343.SGD","LU0234572021.USD","LU2458330169.SGD","SGXZ99366536.SGD","LU0868494617.USD","LU0106261372.USD","LU0557290698.USD","BK4023","LU0082616367.USD","LU0511384066.AUD","BK4534","LU0061474960.USD","LU0942090050.USD","CSBR","LU0965509101.SGD","LU0057025933.USD","LU0158827948.USD","BK4139","LU1720051017.SGD","LU0069063385.USD","LU0868494708.USD","LU0792757196.USD","ADBE","LU1778281490.HKD","IE00B19Z9505.USD","BK4554","LU1267930730.SGD","LU1712237335.SGD","BK4567","DBV","LU2125154778.USD","BK4533","BK4528","LU2237438978.USD","LU2360032135.SGD","LU1815333072.USD","BK4581","BK4585","LU1633808545.USD","LU2236285917.USD","LU0957791311.USD","DBVT","LU0889565833.HKD","LU2089283258.USD","LU2210149790.SGD"],"gpt_icon":1},{"id":"2490819185","title":"Champions Oncology Shares Rise on Higher 2Q Profit, Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2490819185","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490819185?lang=en_us&edition=fundamental","pubTime":"2024-12-12 06:32","pubTimestamp":1733956320,"startTime":"0","endTime":"0","summary":"Shares of Champions Oncology jumped after the company swung to a profit and reported higher revenue in the latest quarter due to bookings growth and operational improvements.The company's stock rose 13% to $6.62 in after-hours trading Wednesday. Shares were up almost 4% for the year through the day's close.The technology-enabled research company on Wednesday posted a profit of $728,000, or 5 cents a share, up from a loss of $2 million, or 15 cents a share, in the same quarter a year ago.Sales grew 17% to $13.5 million from $11.6 million a year earlier, driven by growth in bookings and operational improvements and efficiencies implemented in the quarter.Cost of oncology services rose 12.2% to $7.4 million from $6.6 million a year ago, due to an increase in mice and lab costs to help revenue growth.\"We remain cautiously optimistic that the pharma and biotech environment is improving which will continue to contribute to our long-term growth,\" Chief Executive Ronnie Morris said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2490781395","title":"Champions Oncology Inc reports results for the quarter ended October 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2490781395","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490781395?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:31","pubTimestamp":1733952712,"startTime":"0","endTime":"0","summary":"* Champions Oncology Inc    reported quarterly adjusted earnings of 5 cents per share for the quarter ended October 31, higher than the same quarter last year, when the company reported EPS of -15 cen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2490186198","title":"Champions Oncology Q2 Adj EPS $0.05 Up From $(0.15) YoY, Sales $13.5M Up From $11.6M YoY.","url":"https://stock-news.laohu8.com/highlight/detail?id=2490186198","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490186198?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:06","pubTimestamp":1733951210,"startTime":"0","endTime":"0","summary":"zz","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/wiim/24/12/42448027/champions-oncology-q2-adj-eps-0-05-up-from-0-15-yoy-sales-13-5m-up-from-11-6m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Champions Oncology Q2 Adj EPS $0.05 Up From $(0.15) YoY, Sales $13.5M Up From $11.6M YoY.","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2490188138","title":"Champions Oncology Q2 Adjusted EPS USD 0.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2490188138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490188138?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:00","pubTimestamp":1733950857,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nPLXC51A12:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSBR","BK4121"],"gpt_icon":0},{"id":"2490133558","title":"Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2490133558","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490133558?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:00","pubTimestamp":1733950800,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. , a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.For the second quarter of fiscal 2025, Champions reported income from operations of $732,000, including $9,000 in stock-based compensation and $399,000 in depreciation and amortization expenses, compared to a loss from operations of $2.0 million, inclusive of $53,000 in stock-based compensation and $484,000 in depreciation and amortization expenses, in the second quarter of fiscal 2024. Excluding stock-based compensation, depreciation and amortization expenses, Champions reported adjusted EBITDA of $1.1 million for the second quarter of fiscal 2025 compared to an adjusted EBITDA loss of $1.4 million in the second quarter of fiscal 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-reports-quarterly-revenue-210000279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSBR"],"gpt_icon":0},{"id":"2490379898","title":"North American Morning Briefing: Stock Futures Muted Ahead of CPI Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2490379898","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490379898?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:06","pubTimestamp":1733915160,"startTime":"0","endTime":"0","summary":"Stock futures were muted on Wednesday, split between small gains and losses, ahead of crucial CPI data.Today's inflation data will offer the final major read on the economy before the Federal Reserve's rate decision next week.Investors have grown more confident in recent weeks that central bankers will continue to bring rates lower, with futures prices showing a more than four-in-five chance that the Fed cuts rates by a quarter-percentage point this month.In currency markets, the yuan slipped against the dollar following a Reuters report that China is considering letting its currency weaken next year, as it braces for higher tariffs from the Trump administration.Dave & Buster's Entertainment tumbled after it posted a wider fiscal adjusted loss than analysts estimated and said CEO Chris Morris resigned.Figs  rose 14% after it received a takeover offer from private-equity firm Story3 Capital Partners that values the company at more than $1 billion, the Wall Street Journal reported.GameSt","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a0297e0a0635e442e1e83a7e6a6fe853","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US5Y.BOND","BK4107","LU0061474960.USD","SG9999015978.USD","MIMI","LU0053666078.USD","US12M.BOND","LU0965509283.SGD","IE00BSNM7G36.USD","LU0006306889.USD","RILY","SG9999001424.SGD","US30Y.BOND","LU0511384066.AUD","LU1674673428.USD","CMAXQ","BK4218","M","BK4170","ENSV","LU1815333072.USD","MAYS","BK4233","TSLA","BK4581","NAPA","IHT","KEQU","CGNT","LU2602419157.SGD","US2Y.BOND","SG9999015986.USD","US3Y.BOND","BK4511","CSBR","IMMR","US7Y.BOND","US6M.BOND","AFG","LU0057025933.USD","IE00BWXC8680.SGD","ET","JILL","LLFLQ","US10Y.BOND","ADBE","BK4567","BK4127","LU1861559042.SGD","LU0069063385.USD"],"gpt_icon":1},{"id":"2490088973","title":"Champions Oncology Inc  expected to post earnings of 1 cent a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2490088973","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490088973?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:02","pubTimestamp":1733778148,"startTime":"0","endTime":"0","summary":"Champions Oncology Inc  expected to post earnings of 1cent a share - Earnings Preview Champions Oncology Inc CSBR.OQ CSBR.O is expected to show a rise in quarterly revenue when it reports  results on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL8N3NA1Y4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2489269874","title":"Champions Oncology Inc    expected to post earnings of 1 cent a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2489269874","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489269874?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:03","pubTimestamp":1733518987,"startTime":"0","endTime":"0","summary":"* Champions Oncology Inc     is expected to show a rise in quarterly revenue when it reports  results on December 11 for the period ending October 31 2024   * The Hackensack New Jersey-based  company ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Champions Oncology Inc    expected to post earnings of 1 cent a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSBR"],"gpt_icon":0},{"id":"2489416741","title":"Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2489416741","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489416741?lang=en_us&edition=fundamental","pubTime":"2024-12-06 05:30","pubTimestamp":1733434200,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. , a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST . To join the call dial 888-506-0062  or 973-528-0011  and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010  or 919-882-2331  and entering passcode: 51750, or by accessing the investors section of the company's website within 72 hours.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-announce-second-quarter-213000300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PDX","CSBR","BK4121"],"gpt_icon":1},{"id":"2483027859","title":"New order for Alfa Laval to unlock potential of biofuels in aviation","url":"https://stock-news.laohu8.com/highlight/detail?id=2483027859","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483027859?lang=en_us&edition=fundamental","pubTime":"2024-11-13 16:35","pubTimestamp":1731486900,"startTime":"0","endTime":"0","summary":"LUND, Sweden, Nov. 13, 2024 /PRNewswire/ -- Driving the global energy transition towardsbiofuels, Alfa Laval has secured two contracts worth 350 millionSEK to supply cutting-edge HVO pre-treatment technology to Europe's largest biofuel facility. The facility, a joint venture between Cepsa Bioenergia San Roque S.L. , and Bio-Oils Energy, part of the Apical Group, will produce 500,000 tonnes of sustainable aviation fuel  and renewable diesel annually, addressing the growing demand for cleaner, renewable energy sources.Biofuels are crucial in the decarbonization of our societies, providing a low-carbon solution for existing technologies. In the transportation sector, they play a significant role in the shift towards net-zero emissions. However, the current demand for biofuels far exceeds the available supply, highlighting the need for increased production and innovation to meet this growing need.We pioneer technologies and solutions that free our customers to unlock the true potential of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tu2wkHZsb0a9TKrcRp08.g--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c6b7ac156550c59f71e72b0239e20fc8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tu2wkHZsb0a9TKrcRp08.g--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c6b7ac156550c59f71e72b0239e20fc8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/order-alfa-laval-unlock-potential-083500336.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/order-alfa-laval-unlock-potential-083500336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","BK4161","CSBR","ALFVY","ALFVF"],"gpt_icon":0},{"id":"2480057643","title":"Champions Oncology (NASDAQ:CSBR) shareholders have endured a 61% loss from investing in the stock three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2480057643","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480057643?lang=en_us&edition=fundamental","pubTime":"2024-11-04 18:52","pubTimestamp":1730717547,"startTime":"0","endTime":"0","summary":"Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of Champions Oncology, Inc.  have had an unfortunate run in the last three years. Unfortunately, they have held through a 61% decline in the share price in that time. And the ride hasn't got any smoother in recent times over the last year, with the price 30% lower in that time. Unfortunately the share price momentum is still quite negative, with prices down 16% in thirty days.So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.Check out our latest analysis for Champions Oncology. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the rad","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qUsXHnhTq9BjFq.vX6I3sw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qUsXHnhTq9BjFq.vX6I3sw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-nasdaq-csbr-shareholders-105227713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","SQQQ","IE00B64PRP62.GBP","BK4112","NDAQ","MNQmain","TQQQ","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4121","LU2095319765.USD","PSQ","IE00BKPKM429.USD","NQmain",".IXIC","QID","CSBR","QLD","LU2210150020.SGD","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2475133910","title":"Champions Oncology Signs Licensing Deal With Weill Cornell Medicine For Hematological Xenograft Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2475133910","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475133910?lang=en_us&edition=fundamental","pubTime":"2024-10-16 23:42","pubTimestamp":1729093356,"startTime":"0","endTime":"0","summary":"Champions Oncology  said Wednesday that it signed a licensing agreement with Weill Cornell Medicine, allowing it to distribute and commercialize the latter's hematological patient-derived xenograft models.Under the deal, Champions Oncology will have exclusive rights to offer services that use Weill Cornell Medicine's xenograft models for a limited time, according to the statement. The company said it will also serve as a repository for the models' distribution to academic institutions globally.No financial details were disclosed.Price: 4.45, Change: -0.09, Percent Change: -1.98","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSBR","BK4121"],"gpt_icon":0},{"id":"2475914046","title":"Champions Oncology enters agreement with Weill Cornell Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2475914046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475914046?lang=en_us&edition=fundamental","pubTime":"2024-10-16 23:10","pubTimestamp":1729091408,"startTime":"0","endTime":"0","summary":"Champions Oncology announced a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing, part of Enterprise Inno...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/champions-oncology-enters-agreement-with-weill-cornell-medicine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/champions-oncology-enters-agreement-with-weill-cornell-medicine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSBR","BK4121"],"gpt_icon":0},{"id":"2476946934","title":"Champions Oncology Announces Agreement with Weill Cornell Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2476946934","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476946934?lang=en_us&edition=fundamental","pubTime":"2024-10-16 22:55","pubTimestamp":1729090500,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. , a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing , part of Enterprise Innovation at Weill Cornell Medicine. This strategic collaboration will allow Champions Oncology to distribute and commercialize Weill Cornell Medicine's extensive bank of hematological patient-derived xenograft  models, generated by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at the institution and a member of the Englander Institute for Precision Medicine and Sandra and Edward Meyer Cancer Center.The Center for Technology Licensing at Weill Cornell Medicine played a crucial role in negotiating the licensing agreement and brokering this relationship with Champions Oncology as part of Enterprise Innovation's mission to accelerate the best of biomedical innovation to market and tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-announces-agreement-weill-145500039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSBR","BK4121","PDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.championsoncology.com","stockEarnings":[{"period":"1week","weight":0.2252},{"period":"1month","weight":1.2777},{"period":"3month","weight":1.2532},{"period":"6month","weight":1.1},{"period":"1year","weight":0.7101},{"period":"ytd","weight":0.2252}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.388889,"avgChangeRate":0.081606},{"month":2,"riseRate":0.647059,"avgChangeRate":0.020937},{"month":3,"riseRate":0.388889,"avgChangeRate":0.027512},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.012535},{"month":5,"riseRate":0.5,"avgChangeRate":0.06583},{"month":6,"riseRate":0.444444,"avgChangeRate":0.037812},{"month":7,"riseRate":0.388889,"avgChangeRate":-0.027864},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.014946},{"month":9,"riseRate":0.611111,"avgChangeRate":0.101705},{"month":10,"riseRate":0.277778,"avgChangeRate":0.013574},{"month":11,"riseRate":0.388889,"avgChangeRate":-0.001447},{"month":12,"riseRate":0.555556,"avgChangeRate":0.132235}],"exchange":"NASDAQ","name":"Champions Oncology","nameEN":"Champions Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Champions Oncology(CSBR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Champions Oncology(CSBR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Champions Oncology,CSBR,Champions Oncology股票,Champions Oncology股票老虎,Champions Oncology股票老虎国际,Champions Oncology行情,Champions Oncology股票行情,Champions Oncology股价,Champions Oncology股市,Champions Oncology股票价格,Champions Oncology股票交易,Champions Oncology股票购买,Champions Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Champions Oncology(CSBR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Champions Oncology(CSBR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}